Pfizer market cap is $220.8 b, and annual revenue was $41.91 b in FY 2020

Pfizer Gross profit (FY, 2020)33.2 B

Pfizer Gross profit margin (FY, 2020), %79.3%

Pfizer Net income (FY, 2020)9.7 B

Pfizer Cash, 31-Dec-20201.8 B

Pfizer EV260.8 B

Pfizer revenue was $41.91 b in FY, 2020

Pfizer revenue breakdown by business segment: 19.8% from Upjohn, 76.2% from Biopharma and 4.1% from Other

Pfizer revenue breakdown by geographic segment: 16.8% from Developed Europe, 46.1% from United States, 24.6% from Emerging Markets and 12.5% from Developed Rest of World

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Revenue | 52.5b | 53.6b | 51.8b | 41.9b |

| (1%) | 2% | (4%) | |

## Cost of goods sold | 11.2b | 11.2b | 10.2b | 8.7b |

## Gross profit | 41.3b | 42.4b | 41.5b | 33.2b |

| 79% | 79% | 80% | 79% |

## R&D expense | 7.7b | 8.0b | 8.7b | 9.4b |

## General and administrative expense | 14.8b | 14.5b | 14.4b | 11.6b |

## Operating expense total | 27.2b | 27.4b | 27.6b | 21.0b |

## Depreciation and amortization | 4.8b | 4.9b | 4.6b | |

## Pre tax profit | 12.3b | 11.9b | 17.7b | 7.5b |

## Income tax expense | (9.0b) | 706.0m | 1.4b | 477.0m |

## Net Income | 21.3b | 11.2b | 16.3b | 9.7b |

## EPS | 3.5 | 1.9 | 2.9 |

USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 12.9b | 13.5b | 13.3b | 13.1b | 13.3b | 12.7b | 12.0b | 11.8b | 12.1b |

## Cost of goods sold | 2.6b | 2.9b | 2.7b | 2.4b | 2.6b | 2.6b | 2.4b | 2.3b | 2.5b |

## Gross profit | 10.3b | 10.6b | 10.6b | 10.7b | 10.7b | 10.1b | 9.7b | 9.5b | 9.6b |

| 80% | 78% | 80% | 81% | 81% | 79% | 80% | 81% | 79% |

## R&D expense | 1.7b | 1.8b | 2.0b | 1.7b | 1.8b | 2.3b | 1.7b | 2.1b | 2.4b |

## General and administrative expense | 3.4b | 3.5b | 3.5b | 3.3b | 3.5b | 3.3b | 2.9b | 3.0b | 3.0b |

## Operating expense total | 6.4b | 6.5b | 6.8b | 6.2b | 6.5b | 6.8b | 5.5b | 6.1b | 6.3b |

## Depreciation and amortization | 1.2b | 1.2b | 1.3b | 1.2b | 1.2b | 1.2k | 885.0m | 905.0m | 898.0m |

## Pre tax profit | 4.1b | 4.5b | 4.2b | 4.3b | 4.1b | 10.7b | 3.9b | 4.0b | 2.2b |

## Income tax expense | 556.0m | 648.0m | 66.0m | 433.0m | (915.0m) | 3.0b | 475.0m | 519.0m | (26.0m) |

## Net Income | 3.6b | 3.9b | 4.1b | 3.9b | 5.1b | 7.7b | 3.4b | 3.4b | 2.2b |

## EPS | 0.6 | 0.7 | 0.7 | 0.7 | 0.9 | 1.4 | 0.6 | 0.6 | 0.4 |

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Cash | 1.3b | 1.1b | 1.3b | 1.8b |

## Accounts Receivable | 8.2b | 8.0b | 8.7b | 7.9b |

## Inventories | 7.6b | 7.5b | 8.3b | 8.0b |

## Current Assets | 41.1b | 49.9b | 32.8b | 35.1b |

## PP&E | 13.9b | 13.4b | 14.0b | 13.9b |

## Goodwill | 56.0b | 53.4b | 58.7b | 49.6b |

## Total Assets | 171.8b | 159.0b | 167.5b | 154.2b |

## Accounts Payable | 4.7b | 4.7b | 4.2b | 4.3b |

## Dividends Payable | 2.0b | 2.0b | 2.1b | 2.2b |

## Short-term debt | 10.0b | 13.6b | 17.7b | 4.7b |

## Current Liabilities | 30.4b | 31.9b | 37.3b | 25.9b |

## Long-term debt | 33.5b | 32.9b | 36.0b | 37.1b |

## Total Debt | 43.5b | 32.9b | 53.6b | 41.8b |

## Total Liabilities | 100.1b | 95.7b | 104.0b | 90.8b |

## Common Stock | 464.0m | 467.0m | 468.0m | 470.0m |

## Preferred Stock | 21.0m | 19.0m | 17.0m | |

## Additional Paid-in Capital | 84.3b | 86.3b | 87.4b | 88.7b |

## Retained Earnings | 85.3b | 89.6b | 97.7b | 96.8b |

## Total Equity | 71.7b | 63.8b | 63.4b | 63.5b |

## Debt to Equity Ratio | 0.6 x | 0.5 x | 0.8 x | |

## Debt to Assets Ratio | 0.3 x | 0.2 x | 0.3 x | |

## Financial Leverage | 2.4 x | 2.5 x | 2.6 x | 2.4 x |

USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|

## Net Income | 21.4b | 11.2b | 16.3b | 9.7b |

## Depreciation and Amortization | 6.3b | 6.4b | 6.0b | |

## Accounts Receivable | 259.0m | (644.0m) | (742.0m) | (1.2b) |

## Inventories | (357.0m) | (717.0m) | (1.0b) | (736.0m) |

## Accounts Payable | 46.0m | 431.0m | (564.0m) | 353.0m |

## Cash From Operating Activities | 16.5b | 15.8b | 12.6b | 14.4b |

## Purchases of PP&E | (2.0b) | (2.0b) | (2.2b) | (2.3b) |

## Cash From Investing Activities | (4.7b) | 4.5b | (3.9b) | (4.3b) |

## Short-term Borrowings | (10.0b) | (4.4b) | (8.4b) | (22.2b) |

## Long-term Borrowings | (6.2b) | (3.6b) | (6.8b) | (4.0b) |

## Dividends Paid | (7.7b) | (8.1b) | (8.2b) | (8.6b) |

## Cash From Financing Activities | (13.0b) | (20.4b) | (8.5b) | (9.6b) |

## Net Change in Cash | (1.3b) | (205.0m) | 125.0m | 475.0m |

## Interest Paid | 1.5b | 1.3b | 1.6b | 1.6b |

## Income Taxes Paid | 2.5b | 3.7b | 3.7b | 3.2b |

USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | 3.6b | 7.4b | 11.6b | 3.9b | 8.9b | 16.6b | 3.4b | 6.8b | 9.0b |

## Depreciation and Amortization | 1.6b | 3.1b | 4.7b | 1.5b | 3.1b | 4.6b | 1.2b | 2.5b | 3.7b |

## Cash From Operating Activities | 2.0b | 5.8b | 11.1b | 1.7b | 4.3b | 8.8b | 3.1b | 6.7b | 8.8b |

## Purchases of PP&E | (386.0m) | (810.0m) | (1.4b) | (460.0m) | (939.0m) | (1.5b) | (463.0m) | (942.0m) | (1.5b) |

## Cash From Investing Activities | 9.7b | 8.2b | 5.3b | 7.6b | 5.6b | (1.1b) | (71.0m) | (13.1b) | (12.6b) |

## Short-term Borrowings | (83.0m) | (2.9b) | (4.2b) | (3.8b) | (2.4b) | (4.1b) | (7.6b) | (13.2b) | (17.4b) |

## Long-term Borrowings | (355.0m) | (3.1b) | (3.1b) | (3.0b) | (5.4b) | (5.8b) | (2.2b) | (2.2b) | (2.5b) |

## Dividends Paid | (2.0b) | (4.0b) | (6.0b) | (68.0m) | (4.1b) | (6.1b) | (71.0m) | (4.3b) | (6.4b) |

## Cash From Financing Activities | (10.7b) | (12.6b) | (14.0b) | (8.5b) | (9.3b) | (6.0b) | (2.2b) | 7.0b | 4.1b |

## Net Change in Cash | 985.0m | 1.4b | 2.2b | 792.0m | 612.0m | 1.6b | 846.0m | 495.0m | 277.0m |

## Interest Paid | 259.0m | 724.0m | 968.0m | 385.0m | 809.0m | 1.2b | 472.0m | 910.0m | 1.3b |

## Income Taxes Paid | 257.0m | 1.2b | 1.7b | 235.0m | 2.1b | 2.6b | 239.0m | 1.3b | 2.4b |

USD | FY, 2017 |
---|---|

## Revenue/Employee | 582.5k |

## Debt/Equity | 0.6 x |

## Debt/Assets | 0.3 x |

## Financial Leverage | 2.4 x |

Pfizer's Properties was reported to be 453 in FY, 2019.

FY, 2019 | |
---|---|

## Water Withdrawn | 15.05 m cubic meters |

## Waste Generated | 1.4 b kilograms |

## Waste Disposed | 103.3 m kilograms |

## Total Greenhouse Gas Emissions | 1.49 m metric tons of carbon dioxide equivalent |

## Nonhazardous Waste Generated | 41.9 m kilograms |

## Nonhazardous Waste (Disposed) | 23 m kilograms |

## Lost Time Incident Rate | 0.16 |

## Hazardous Waste Generated | 98.3 m kilograms |

## Hazardous Waste (Recycled) | 18 m kilograms |

## Hazardous Waste (Disposed) | 80.3 m kilograms |

## Greenhouse Gas Emissions (Scope 2) | 760 k metric tons of carbon dioxide equivalent |

## Greenhouse Gas Emissions (Scope 1) | 730 k metric tons of carbon dioxide equivalent |

## Energy Used | 17.1 m GJ |